Cargando…

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis

BACKGROUND: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. METHODS: We conducted a retrospective cohort study by utilizing multi-insti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Kai-Cheng, Shao, Shih-Chieh, Kuo, Shihchen, Yang, Chen-Yi, Chen, Hui-Yu, Chan, Yuk-Ying, Ou, Huang-Tz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547475/ https://www.ncbi.nlm.nih.gov/pubmed/33036617 http://dx.doi.org/10.1186/s12933-020-01148-8

Ejemplares similares

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020)

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021)

Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes
por: Yang, Chen-Yi, et al.
Publicado: (2020)

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective
por: Su, Hsuan-Yu, et al.
Publicado: (2023)

Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan
por: Peng, Zi-Yang, et al.
Publicado: (2022)

Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review
por: Yang, Chun-Ting, et al.
Publicado: (2022)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
por: Tanaka, Kenichi, et al.
Publicado: (2022)

Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies
por: Yang, Chen-Yi, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
por: Nagaike, Hiroe, et al.
Publicado: (2019)

Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future
por: Kuo, Shihchen, et al.
Publicado: (2021)

Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan
por: Chang, Kai-Cheng, et al.
Publicado: (2022)

Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases
por: Kuo, Shihchen, et al.
Publicado: (2021)

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus
por: Taheri, Saeed, et al.
Publicado: (2019)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
por: Du, Juan, et al.
Publicado: (2023)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
por: Tuttolomondo, Antonino, et al.
Publicado: (2021)

Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study
por: Peng, Zi-Yang, et al.
Publicado: (2023)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
por: van Eyk, Huub J., et al.
Publicado: (2019)

Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes
por: Chen, Xiao-min, et al.
Publicado: (2018)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
por: Shao, Shih-Chieh, et al.
Publicado: (2021)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study
por: Chen, Tien-Hsing, et al.
Publicado: (2020)

Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real‐world experience
por: Lin, Po‐Ting, et al.
Publicado: (2023)

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
por: Ferdinand, Keith C., et al.
Publicado: (2016)

Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
por: Lin, Fang-Ju, et al.
Publicado: (2021)

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
por: Ghosal, S., et al.
Publicado: (2018)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cu1gn86qg7qqm9cvelu2n5lpq0